Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.


NASDAQ | SNSS (Common Stock) $2.91 -0.13
Stock chart for: SNSS.O.  Currently trading at $2.91 with a 52 week high of $4.45 and a 52 week low of $1.82.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the future treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor, SNS-062, treats ibrutinib-resistant chronic lymphocytic leukemia. Sunesis is also supporting investigator-led studies of vosaroxin in acute myeloid leukemia.

More »